肥胖是否与微创二尖瓣手术预后较差相关?
本研究为8年回顾性队列研究,比较BMI≥30 kg/m²与BMI<30 kg/m²患者行微创二尖瓣手术的预后。结果显示两组在修复率、手术时长、围术期结局及5年生存率上均无显著差异,提示肥胖不应被视为该技术的禁忌证。
要点
- 肥胖患者行微创二尖瓣手术的短期与中期结局与非肥胖患者无显著差异。
- 肥胖不应作为经验丰富团队开展微创二尖瓣手术的禁忌证。
- 研究仅纳入296例,肥胖组41例,需谨慎解读。
核心结论
- 在行微创二尖瓣手术的患者中,证据不足以表明肥胖影响短期或中期结局。
- 肥胖不应被视为经验丰富团队开展该技术的禁忌证。
研究设计与样本
- 回顾性队列研究,纳入8年间所有行微创二尖瓣手术±同期手术的患者。
- 按世界卫生组织标准分为BMI≥30 kg/m²组(n=41,中位35.3,范围30-43.6)和BMI<30 kg/m²组(n=255,中位26.2,范围17.6-29.9)。
主要发现
- 院内死亡仅1例,发生在BMI<30组。
- 退行性病变修复率两组分别为100%与96.3%,P>0.99。
- 主动脉阻断时间分别为122分钟(IQR 100-141)与125分钟(IQR 105-146),P=0.72。
- 中转开胸仅6例,均发生在非肥胖组。
- 5年生存率分别为95.8%与95.5%,P=0.83。
临床怎么用
- 对肥胖患者,经验丰富的团队可考虑行微创二尖瓣手术,不因肥胖而排除。
局限性
- 回顾性设计,肥胖组样本量较小(n=41)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: High body mass index (BMI) makes minimally invasive mitral valve surgery (MIMVS) more challenging with some surgeons considering this a contraindication. We sought to determine whether this is because the outcomes are genuinely worse than those of non-obese patients. METHODS: This is a retrospective cohort study of all patients undergoing MIMVS ± concomitant procedures over an 8-year period. Patients were stratified into 2 groups: BMI ≥ 30 kg/m2 and BMI ˂ 30 kg/m2, as per World Health Organization definitions. Baseline characteristics, operative and postoperative outcomes and 5-year survival were compared. RESULTS: We identified 296 patients (BMI ≥30, n = 41, median 35.3, range 30-43.6; BMI <30, n = 255, median 26.2, range 17.6-29.9). The groups were well matched with regard to baseline characteristics. There was only 1 in-hospital mortality, and this was in the BMI < 30 group. There was no difference in repair rate for degenerative disease (100% vs 96.3%, P > 0.99 respectively) or operative durations [cross-clamp: 122 min interquartile range (IQR) 100-141) vs 125 min (IQR 105-146), P = 0.72, respectively]. There were only 6 conversions to sternotomy, all in non-obese patients. There was no significant difference in any other perioperative or post-operative outcomes. Using the Kaplan-Meier analysis, there was no significant difference in 5-year survival between the 2 groups (95.8% vs 95.5%, P = 0.83, respectively). CONCLUSIONS: In patients having MIMVS, there is insufficient evidence to suggest that obesity affects either short- or mid-term outcomes. Obesity should therefore not be considered as a contraindication to this technique for experienced teams.
引用
- Aljanadi F, Toolan C, Theologou T, et al. Is obesity associated with poorer outcomes in patients undergoing minimally invasive mitral valve surgery? Eur J Cardiothorac Surg. 2021. PMID: 32968781. doi:10.1093/ejcts/ezaa274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。